Related Experiment Video
Updated: Jan 16, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy.
Milind Y Desai1, Niccolo Maurizi2, Elena Biagini3
1HCM Center, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Hypertrophic cardiomyopathy (HCM) is a heart condition affecting many globally. This review details nonobstructive HCM, its varied impacts, and current research for new treatments.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) affects over 1 in 500 individuals globally.
- Nonobstructive HCM, comprising 30-70% of cases, is highly heterogeneous.
- It leads to significant morbidity, including heart failure and arrhythmias.
Purpose of the Study:
- To provide a comprehensive overview of nonobstructive HCM.
- To cover epidemiology, natural history, genetics, pathophysiology, and clinical aspects.
- To discuss current treatments and ongoing clinical trials.
Main Methods:
- This is a narrative review.
- Literature search on nonobstructive HCM.
- Synthesis of existing data on the condition.
Main Results:
- Nonobstructive HCM presents with diverse clinical manifestations.
- Genetic factors play a crucial role in its pathophysiology.
- No pharmaceutical therapies are currently approved, but trials are active.
Conclusions:
- Nonobstructive HCM requires further research due to its heterogeneity and burden.
- Understanding its natural history and genetics is key.
- Ongoing trials offer hope for future therapeutic strategies.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology

